Buy Rating Affirmed for Dyne Therapeutics Amid Promising DYNE-251 Data and Strategic Milestones
PremiumRatingsBuy Rating Affirmed for Dyne Therapeutics Amid Promising DYNE-251 Data and Strategic Milestones
17d ago
Promising Advancements and Strategic Positioning of Dyne Therapeutics’ DYNE-251: A Buy Rating Analysis
Premium
Ratings
Promising Advancements and Strategic Positioning of Dyne Therapeutics’ DYNE-251: A Buy Rating Analysis
18d ago
Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
Premium
The Fly
Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
19d ago
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler
PremiumThe FlyDyne Therapeutics price target lowered to $48 from $53 at Piper Sandler
1M ago
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251
Premium
Ratings
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251
1M ago
Dyne Therapeutics price target lowered to $46 from $55 at H.C. Wainwright
Premium
The Fly
Dyne Therapeutics price target lowered to $46 from $55 at H.C. Wainwright
1M ago
H.C. Wainwright keeps Buy on Dyne Therapeutics after data
PremiumThe FlyH.C. Wainwright keeps Buy on Dyne Therapeutics after data
3M ago
RBC remain buyers of Dyne Therapeutics after DM1 and DMD data
Premium
The Fly
RBC remain buyers of Dyne Therapeutics after DM1 and DMD data
3M ago
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD
Premium
Company Announcements
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100